Tag Archives: Circulation

Digital Health: Wearable Sensor Data Can Predict Heart Failure 6 Days Before Hospitalization

From a “Circulation: Heart Failure” Journal study (Feb 25, 2020):

Circulation Heart Failure logoThe study shows that wearable sensors coupled with machine learning analytics have predictive accuracy comparable to implanted devices.

We demonstrate that machine learning analytics using data from a wearable sensor can accurately predict hospitalization for heart failure exacerbation…at a median time of 6.5 days before the admission.

Heart failure (HF) is a major public health problem affecting >23 million patients worldwide. Hospitalization costs for HF represent 80% of costs attributed to HF care. Thus, accurate and timely detection of worsening HF could allow for interventions aimed at reducing the risk of HF admission.

Data collected by the sensor are streamed to a phone and then encrypted and uploaded to a cloud analytics platform.
Data collected by the sensor are streamed to a phone and then encrypted and uploaded to a cloud analytics platform.

Several such approaches have been tested. Tracking of daily weight, as recommended by current HF guidelines, did not lead to reduction of the risk of HF hospitalization, most likely because the weight gain is a contemporaneous or lagging indicator rather than a leading event. Interventions based on intrathoracic impedance monitoring also did not result in reduction of readmission risk. The results suggest that physiological parameters other than weight or intrathoracic impedance in isolation may be needed to detect HF decompensation in a timely manner. In fact, 28% reduction of rehospitalization rates has been shown with interventions based on pulmonary artery hemodynamic monitoring. More recently, in the MultiSENSE study (Multisensor Chronic Evaluation in Ambulatory HF Patients), an algorithm based on physiological data from sensors in the implantable cardiac resynchronization therapy defibrillators, was shown to have 70% sensitivity in predicting the risk of HF hospitalization or outpatient visit with intravenous therapies for worsening of HF.

Read full study

Health Studies: Physician Prescribed Omega-3 Fatty Acids Safely Reduce High Triglyceride Levels

From the journal Circulation on August 19, 2019:

Circulation JournalThe use of n-3 FA (4 g/d) for improving atherosclerotic cardiovascular disease risk in patients with hypertriglyceridemia is supported by a 25% reduction in major adverse cardiovascular events in REDUCE-IT (Reduction of Cardiovascular Events With EPA Intervention Trial), a randomized placebo-controlled trial of EPA-only in high-risk patients treated with a statin.

The results of a trial of 4 g/d prescription EPA+DHA in hypertriglyceridemia are anticipated in 2020. We conclude that prescription n-3 FAs (EPA+DHA or EPA-only) at a dose of 4 g/d (>3 g/d total EPA+DHA) are an effective and safe option for reducing triglycerides as monotherapy or as an adjunct to other lipid-lowering agents.

Hypertriglyceridemia (triglycerides 200–499 mg/dL) is relatively common in the United States, whereas more severe triglyceride elevations (very high triglycerides, ≥500 mg/dL) are far less frequently observed. Both are becoming increasingly prevalent in the United States and elsewhere, likely driven in large part by growing rates of obesity and diabetes mellitus.

To read more click on the following link: https://www.ahajournals.org/doi/10.1161/CIR.0000000000000709

Health Studies: Short Sleep Duration And Sleep Disorders Have Adverse Effects On Heart Health

From a Circulation online release:

Average hours of nightly sleep…these results indicate that sleep may play an important role in health disparities and may represent a modifiable risk factor (along with diet and physical activity) for cardiometabolic risk in general and cardiometabolic health disparities specifically.

Statement Summary

Our review of the epidemiological data on the impact of sleep duration and disorders on cardiovascular health suggests the following:

  1. Both short- and long-duration sleep and sleep disorders such as SDB and insomnia are associated with adverse cardiometabolic risk profiles and outcomes.

  2. Sleep restriction has a negative impact on energy balance, but it is less clear whether treating sleep disorders has a positive impact on obesity risk.

  3. Treating those with sleep disorders may provide clinical benefits, particularly for blood pressure.

Sleep is increasingly recognized as an important lifestyle contributor to health. However, this has not always been the case, and an increasing number of Americans choose to curtail sleep in favor of other social, leisure, or work-related activities. This has resulted in a decline in average sleep duration over time. Sleep duration, mostly short sleep, and sleep disorders have emerged as being related to adverse cardiometabolic risk, including obesity, hypertension, type 2 diabetes mellitus, and cardiovascular disease.

To read more click on the following link: https://www.ahajournals.org/doi/10.1161/CIR.0000000000000444